A life sciences adviser said on Apr. 8 that biotechnology companies must focus on fundamentals to survive the current prolonged market downturn, which is marked by low valuations, fewer financings, and more selective investors. The adviser emphasized that this period of uncertainty and tight capital requires careful preparation in areas beyond scientific innovation.
The topic matters because many biotech firms are struggling to raise funds as they face economic challenges not seen in recent years. The adviser said that great science alone has never been enough to build a successful company, and a lack of preparation for funding realities can now threaten a company's survival.
The article highlights several key strategies for biotech companies: organizing legal and regulatory documents early, aligning financing milestones with scientific achievements, treating compliance as an asset rather than a burden, and building strong governance practices even before considering going public. "If your regulatory and IP foundations are clean, your science looks even stronger," the adviser said.
Compliance was described as an important driver of value during deals or acquisitions. "Clean compliance is good business," the adviser said, adding that regular audits and clear documentation signal maturity to investors.
Investor selectivity is higher than ever according to the article's author. Rounds are larger but less frequent, while hybrid financing structures have become more common. However, what investors continue to value most are clarity, control, and compliance.
The article concludes by noting that founders cannot change macroeconomic conditions but can ensure their companies are ready for scrutiny. Legal readiness was described as essential for scientific success.
